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Polymorphonuclear granulocytes (PMNs; neutrophils) serve as key effector cells in the innate immune system and
provide the first line of defense against invading microorganisms. In addition to producing inflammatory cytokines
and chemokines and undergoing a respiratory burst that stimulates the release of reactive oxygen species, PMNs
also degranulate to release components that kill pathogens. Recently, neutrophil extracellular traps have been
shown to be an alternative way to trap microorganisms and contain infection. PMN-derived granule components
are also involved in multiple non-infectious inflammatory processes, including the response to myocardial infarction
(MI). In this review, we will discuss the biological characteristics, recruitment, activation, and removal of PMNs, as
well as the roles of PMN-derived granule proteins in inflammation and innate immunity, focusing on the MI setting
when applicable. We also discuss future perspectives that will direct research in PMN biology.
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Introduction
Polymorphonuclear granulocytes (PMNs; neutrophils) are
a type of leukocyte of approximately 10 μm in diameter
that play vital roles in the innate immunity response to
pathogens. PMNs are the first responders to infection or
injury. Persistent neutropenia leads to increased risk of
microorganism infections, while excessive recruitment and
activation or delayed removal of PMNs results in
tissue damage in inflammatory disorders [1]. Following
myocardial infarction (MI), numbers of circulating PMNs
increase, and the post-MI PMN to lymphocyte ratio has
been reported by Akpek and colleagues to predict major
adverse cardiac events in MI patients [2]. While PMN
counts do not improve the ability to diagnose MI, they are
a prognostic biomarker of chronic remodeling of the
left ventricle (LV) [3]. Increased PMN counts after
percutaneous coronary intervention for ST-elevation
MI associates with larger infarct sizes and worse cardiac
function [4]. Neutrophil depletion reduces infarct size and
the extent of injury in a canine model [5,6]. As such, PMNs
have been shown to mediate MI-induced cardiac injury* Correspondence: yma@umc.edu; mllindsey@umc.edu
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reproduction in any medium, provided the orand remodeling. However, the potential mechanisms by
which neutrophils regulate MI-induced LV remodeling are
not well understood, and PMN depletion strategies in
humans increased adverse outcomes post-MI [7]. This
review will discuss our current understanding of PMN
biology, including recruitment, activation, clearance, and
function. We also discuss the roles of PMN-derived
components in inflammation and innate immunity,
focusing on the MI setting. In addition, we propose future
directions that may advance the PMN research arena.Biological characteristics of PMNs
PMNs are the most abundant leukocyte cell type in
mammals, accounting for ~35-75% of circulating leuko-
cytes under normal conditions [8]. PMNs are the first-line
immune cells recruited to sites of injury as a defense against
microorganisms. PMN microbicidal mechanisms include
receptor-mediated phagocytosis and intracellular killing,
release of antimicrobial granule contents by degranulation,
and the formation of neutrophil extracellular traps (NETs)
[9]. In addition to their antimicrobial activity, growing
evidence suggests that PMNs play an essential role in
non-infectious inflammation, innate immunity, and
tissue remodeling [10].
Based on ex vivo evaluation, murine and human PMNs
have a circulating lifespan of 5–10 h [11,12]. However,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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labeling has shown that the circulating lifespan of
human PMNs can last up to 5.4 days, indicating that
in vivo characteristics of PMNs may be altered by
ex vivo manipulation or that in vivo stimuli can prevent
PMN apoptosis [13]. In the proinflammatory environment,
for example, PMN lifespan can be prolonged by tumor
necrosis factor (TNF)-α- or interleukin (IL)-1β-stimulated
inhibition of apoptosis [14].
PMN development and maturation take place in the
bone marrow. In the presence of growth factors and
cytokines, pluripotent hematopoietic cells differentiate
into myeloblasts, which are the precursor cells of PMNs
[15]. PMNs synthesize components stored in different
granules as part of the maturation process [10]. It is
estimated that PMNs are produced at ~1 × 109 cells per
kilogram body weight daily under physiological conditions
[16]. Only 1-2% of mature PMNs circulate, while 98-99%
remain in the bone marrow [17]. Circulating PMNs are
mature, terminally differentiated cells that have lost their
proliferative capacity. In response to a challenge, mature
PMNs in the bone marrow mobilize into the blood and
are recruited to injury sites. PMN chemoattraction is
regulated by chemokines, cytokines, and microbial
products [1].
PMN extravasation and recruitment in response to MI
In the setting of MI, chemokines that recruit PMNs to sites
of ischemia include macrophage inflammatory protein-2α
(MIP-2α, CXCL2, GRO β), leukotriene B4 (LTB4), CINC-1
(CXCL1, GRO α, KC), IL-8 (CXCL8), and complement 5a
[18,19]. PMN-attracting CXC chemokines are rapidly and
profoundly increased post-MI and have been localized
bound to glycosaminoglycans on endothelial cell surfaces
or in the extracellular matrix. The accumulation of high
concentrations of chemokines at the ischemic site attracts
PMNs to the injury area by interaction with cell surface
chemokine receptors [20].
PMNs leave the circulation and infiltrate to the infarct
region through several sequential steps, collectively known
as extravasation. The extravasation of PMNs occurs
primarily in post-capillary venules, where hemodynamic
shear forces are diminished and the vessel wall is thin. As
a first step, PMNs are arrested from the fast-flowing blood
stream and roll on endothelial cells. This reaction is medi-
ated through binding of P-selectin ligand 1 and L-selectin
constitutively expressed on PMNs to P-selectin, E-selectin,
intercellular adhesion molecules (ICAMs), and vascular
cell adhesion molecules expressed by activated endothelial
cells [15]. Second, firm adhesion occurs by interaction of
the β2 integrin lymphocyte function-associated antigen-1
(αLβ2, LFA-1, CD11a/CD18) and macrophage-1 antigen
(Mac-1, αMβ2, CD11b/CD18, CR3) present on PMNs with
their ligands ICAM-1 and ICAM-2 on endothelial cells.Next, PMN transendothelial migration takes place by
paracellular or intracellular trafficking. While most PMNs
squeeze between endothelial cells (paracellular trafficking),
a small fraction penetrates and passes through pores in
the cytoplasm of individual endothelial cell (intracellular
trafficking) [15]. Mediators that guide migration are the
same as those of firm adhesion, namely integrins αLβ2 and
αMβ2, ICAM-1, and ICAM-2. PMN homing to the infarct
site is similar to PMN extravasation into other tissues as
part of a common wound healing response to injury.
In the absence of reperfusion, PMNs are the first
inflammatory cells recruited to the infarct area. With
permanent occlusion in C57BL/6J mice, PMN infiltration
occurs within hours post-MI, peaks at days 1–3, starts to
decline at day 5, and is present at very low levels from day
7 post-MI (Figure 1). As such, PMNs primarily regulate
the early LV remodeling response. PMNs initiate the acute
inflammatory response to engulf dead cells and tissue
debris and facilitate post-MI repair. However, excessive
PMN infiltration or delayed regression exacerbates tissue
injury by the abundant release of inflammatory mediators
and proteinases [21]. Hence, PMN infiltration and removal
need to be tightly controlled.
PMN activation post-MI
In response to infection, PMNs can be activated by
pathogen-associated molecular patterns from pathogens
or danger-associated molecular patterns (DAMPs) from
host tissue via engagement with pattern recognition
receptors expressed on the surface or within the cytoplasm
of PMNs. PMNs express a wide array of pattern recognition
receptors, including 12 of the13 known toll-like receptors
(TLRs; the exception is TLR3), C-type lectin receptors
dectin 1 (CLEC7A) and CLEC2, NOD-like receptors
(NLRs), and cytoplastic sensors of ribonucleic acids, includ-
ing retinoic acid-inducible gene 1 (RIG-I) and melanoma
differentiation-associated protein 5 (MDA5) [22-26].
Activated PMNs kill invading pathogens by the mecha-
nisms of release of reactive oxygen species (ROS) and
granule proteins, as well as NETs. However, uncontrolled
PMN accumulation can lead to injury to host tissue
and cells.
DAMPs are molecules that can initiate and perpetuate
the immune response in non-infectious inflammatory
conditions, and DAMPs are produced from host
tissue or immune cells in response to stress or injury.
MI-associated DAMPs include heat shock proteins,
high-mobility group box (HMGB)-1, low molecular
hyaluronic acid, and fibronectin fragments [27]. DAMPs, as
endogenous danger signal and secondary injury-promoting
factors, engage with pattern recognition receptors to
activate PMNs, other immune cells, or parenchymal cells
[28]. This leads to the development of a proinflammatory
autocrine loop that can result in chronic or unresolved
Figure 1 Time course of PMN infiltration post-MI. MI was created by permanent ligation of the left anterior descending coronary artery in
C57BL/6J mice. Following MI, PMN infiltration peaked at days 1–3, started to decline at day 5, and was present at very low levels from day 7 post-
MI. PMNs were stained with anti-mouse neutrophil monoclonal antibody (Cederlane, CL8993AP, 1:100). Representative images from n = 3 stained
samples per group. Our own unpublished data.
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for TLR2 and TLR4, is released both actively and passively
by injured cells [29]. Injection of HMGB1 results in PMN
accumulation, and an anti-HMGB1 blocking antibody
inhibits PMN infiltration in lipopolysaccharide-induced
lung injury [30]. HMGB1, therefore, promotes and sustains
the inflammatory response.PMN clearance and resolution of inflammation
Apoptotic PMNs are removed by macrophage- or dendritic
cell-mediated phagocytosis. In the absence of infection or
inflammation, PMN clearance occurs at significant rates in
the spleen, liver, and bone marrow [31]. In response to
infection or inflammation, PMNs can infiltrate in and be
cleared from all tissues of the body [21]. PMN apoptosis as
well as subsequent removal is a hallmark of inflammation
resolution, an active process that requires activation of
many inhibitory pathway cascades [20]. For example, apop-
totic PMNs produce “find me” (e.g., lipid mediators and
nucleotides) and “eat me” (e.g., lysophosphatidylcholine)
signals to attract scavengers by at least two different
mechanisms [20,21]. First, apoptotic PMNs generate
annexin A1 and lactoferrin to inhibit PMN infiltration.
Moreover, these two mediators attract phagocytic macro-
phages to remove PMNs. Second, phagocytosis of apoptotic
PMNs by macrophages activates an antiinflammatory
pathway to inhibit proinflammatory mediators (e.g., TNF-α)
and induce the production of IL-10, transforming growth
factor-β and pro-resolving lipid mediators such as lipoxins,
protectins, and resolvins [32]. These pro-resolving media-
tors inhibit PMN transendothelial migration and scavenge
chemokines and cytokines. Esmann and colleagues haverecently shown that after exposure to activating stimuli
(e.g., lipopolysaccharide and interferon-γ), PMNs, as a
self-regulation mechanism, can ingest apoptotic PMNs
and contribute to the resolution of acute inflammation
[33]. If not removed in a timely manner, dying PMNs can
liberate granule components to the extracellular environ-
ment and prolong the ongoing inflammatory response [21].
The importance of these mechanisms in the MI setting,
however, needs to be investigated.ROS and MI
Upon contact with proinflammatory stimuli (e.g., cytokines
and growth factors), PMNs release large amounts of ROS
through a process known as the respiratory burst [34]. The
respiratory burst is mediated by nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase multicomponent
enzyme. NAPDH oxidase is composed of a membrane-
bound cytochrome b558 consisting of gp91phox and
p22phox, cytosolic subunit p67phox, p47phox, and
p40phox, and the small G-protein Rac (Rac1 or Rac2)
[35]. In resting PMNs, the NAPDH oxidase complex
is not assembled. Upon activation, these subunits
assemble into an active enzyme complex that catalyzes the
production of ROS [34].
The generation of ROS is an indispensable contributor
of PMN antimicrobial activity and provides one of the
most efficient microbicidal mechanisms [34]. NADPH
oxidase increases ROS production. ROS can directly
damage host tissue and cells by modifying amino acids,
proteins, and lipids to alter their biological functions [10].
For example, ROS can oxidize cysteine residues to regulate
the activities of phosphatases, metalloproteinases, and
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microvascular density in the infarct region at day 7 post-MI
, and inhibition of NADPH oxidase attenuates post-MI
cardiac fibrosis in rats or rabbits, indicating pro-angiogenic
and pro-fibrotic roles of ROS [36-38]. While an appropriate
amount of ROS generation is beneficial to post-MI cardiac
repair, excessive ROS are detrimental.
PMN granule components
PMNs play a critical role in protecting against pathogen in-
fection and non-infectious inflammatory processes, and its
functions depend on the exocytosis and release of PMN
granule components. There are four types of PMN gran-
ules, which combined contain approximately 300 proteins:
azurophilic (primary), specific (secondary), gelatinase (ter-
tiary), and secretory granules (Figure 2). Azurophilic gran-
ules, the largest, are first formed during PMN maturation
and contain myeloperoxidase (MPO), serine proteases,
azurocidin, α-defensins, lysozyme, and bactericidal/perme-
ability-increasing protein [10]. Specific granules are smaller
than azurophilic granules in diameter and contain lactofer-
rin, neutrophil gelatinase-associated lipocalin (NGAL,
lipocalin-2), cathelicidin, and lysozyme [39]. Gelatinase
granules are smaller than specific granules and contain
multiple matrix metalloproteinases (MMP-8 and −9 in par-
ticular) and a few microbicidal materials. Secretory granules
consist primarily of complement receptor 1, plasma protein
albumin, CD13 (aminopeptidase N), CD14, and CD16 (Fc
gamma receptor III) [10].
PMN granules are sequentially mobilized into the tissue
during cell migration. Secretory granules are discharged
first, and these components interact with the endothelium
and other leukocytes in the circulation. Gelatinase
degranulation occurs during transendothelial migration ofFigure 2 PMN granules. The types, components, formation order, granule
components that have been evaluated in the MI setting are highlighted in
neutrophil gelatinase-associated lipocalin; NRAMP1: natural resistance assocPMNs, followed by the release of specific and azurophilic
granules at the site of inflammation [40]. In addition to
antimicrobial functions, these granule components are
involved in a number of inflammation-associated diseases,
including MI. Below, we summarize the current literature
on the roles of granule components in post-MI LV
remodeling. For granule components that have not
been studied in the MI setting, we discuss their roles
in regulating inflammation and innate immunity.
Granule components evaluated in the MI setting
Myeloperoxidase (MPO)
MPO is an enzyme that catalyzes the oxidation of halide
ions to hypohalous acids mediated by hydrogen peroxide,
which modifies amino acids and many kinds of macromole-
cules and affects their normal biological properties [41]. In
addition to acting as a key component of the oxygen-
dependent intracellular microbicidal system, MPO is
involved in tissue injury and remodeling. MPO is elevated
in MI patients and can act as a diagnostic plasma marker of
MI [42]. High MPO is also a risk factor for long-term
mortality [43]. Post-MI, MPO is secreted by PMNs and
macrophages, and it accumulates in infarct regions to
oxidize proteins and lipids. MPO deletion in mice reduces
leukocyte infiltration and also attenuates LV function and
dilatation, which have been shown in part to be due to
decreased oxidative inactivation of plasminogen activator
inhibitor 1 [44]. In addition, MPO generates cytotoxic
products of glycine (formaldehyde) and threonine (acrolein)
in the infarct zone, which adversely affects LV remodeling
and function in mice [45]. Reactive chlorinating species
produced by MPO catalyze plasmalogens to produce the
alpha-chloro fatty aldehyde 2-chlorohexadecanal, which
elicits myocardial damage and reduces ventricularsize, and degranulation order of PMN granules. The granule
green. BPI: Bactericidal/permeability-increasing protein; NGAL:
iated macrophage protein-1; CR1: complement receptor 1.
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represent a promising way to alleviate MI-induced LV
remodeling.
Serine proteases
Serine proteases stored in azurophilic granules include
neutrophil elastase (NE), cathepsin G, proteinase 3, and
neutrophil serine protease-4. Neutrophil serine protease-4
has recently been identified and shows 39% identity to NE
and proteinase 3 [47]. In the presence of ROS, serine
proteinases can break down internalized pathogens, pro-
teolytically degrade cytokines and chemokines, and activate
cell surface receptors [48]. In addition, serine proteinases
activate the coagulation cascade and platelets to stimulate
thrombus formation [49]. During systemic infection,
activation of coagulation facilitates compartmentalization
of pathogens in liver microvessels and limits infection
expansion. In contrast, in the absence of microorganism
challenge, coagulation induces large vessel thrombosis and
contributes to a risk for MI and stroke.
NE degrades elastin, collagens, and fibrinogen and
contributes to cardiac damage post-MI. NE induces IL-6
secretion to impair cardiac contractility by a nitric oxide-
dependent pathway [50]. NE can cleave and activate pro-
MMP-9, indicating an interactive action of PMN-derived
molecules [51]. NE is released in the early stages of
ischemia, and inhibition of NE has been shown to reduce
infarct size [52]. Similarly, a selective NE inhibitor protects
against myocardial stunning after ischemia/reperfusion in
swine [53]. Proteinase 3 is stored in both azurophilic
and secretory granules. Proteinase 3 induces endothelial
cell apoptosis by caspase-like activity [54], cleaves
angiotensinogen to generate angiotensin I and II [55],
activates proinflammatory factors (e.g., TNF-α, IL-1β, and
IL-18), and degrades extracellular matrix (e.g., fibronectin
and collagen IV) [56]. Proteinase 3 levels in the plasma are
higher in chronic post-MI patients who later die or are re-
admitted for heart failure compared to event-free survivors
[56]. This indicates that proteinase 3 may exacerbate heart
failure and serve as a prognostic marker.
NGAL
NGAL is a glycoprotein with bacteriostatic properties
stored in specific granules of mature PMNs. In humans,
NGAL binds directly with MMP-9 to form a high molecu-
lar weight complex, protecting MMP-9 from degradation
[57]. This binding occurs at the 87 amino acid of the
NGAL, which is a cysteine in humans [58]. Mouse NGAL
does not have this cysteine and does not bind directly to
MMP-9. NGAL levels significantly increase in both rats
and patients post-MI and associate with adverse outcomes
[59]. High plasma NGAL before intervention has been
shown to independently predict all-cause mortality for MI
patients treated with primary percutaneous coronaryintervention [60]. The NGAL mechanisms of regulating
LV remodeling have not been revealed, but may involve
both direct interactions with MMP-9 as well as growth
factor functions independent of complex formation.MMP-8
Despite originally being classified as the neutrophil colla-
genase, MMP-8 is secreted not only by PMNs, but also by
macrophages [61]. MMP-8 promotes PMN migration by
degrading collagens [62], and PMN depletion inhibits
early collagen degradation because of the lack of MMP-8
[63]. MMP-8 degrades fibrillar collagen by binding and
cleavage of collagen type I α1 and α 2 chains [64]. The
quantities of total and active MMP-8 were shown to be
higher in patients with LV rupture than those without
rupture [65], indicating that MMP-8 may promote infarct
rupture in humans by degrading collagen.MMP-9
MMP-9 is one of the most widely investigated MMPs in
cardiovascular disease. Infiltrating PMNs are an early source
of MMP-9 after MI both with and without reperfusion in
humans and multiple animal models, including mice, rab-
bits, and canines [66-69]. PMN-derived MMP-9 is stored in
gelatinase granules and released upon chemotactic stimula-
tion. MMP-9 is also be secreted by macrophages, myocytes,
fibroblasts, vascular smooth muscle cells, and endothelial
cells [61]. MMP-9 is significantly elevated in the first week
after MI in mice, consistent with the time course of PMN
and macrophage infiltration. MMP-9 deletion attenuates
LV dysfunction and collagen deposition and promotes
angiogenesis post-MI in mice [70,71]. Neutrophil-derived
MMP-9 may exert very early effects in the MI setting by de-
grading extracellular matrix and promoting leukocyte cell
infiltration into the infarct area, while MMP-9 from other
cells may regulate scar formation [72,73].Granule components that have not been evaluated in the
MI setting
Cathepsin G
Cathepsin G has biphasic regulation of leukocyte
chemotaxis, serving as both a stimulator and repressor
of chemotaxis. Substrate availability determines its action,
as cathepsin G enhances PMN and monocyte chemotaxis
by cleaving the N-terminal residues of CXCL5 and CCL15
to increase their chemotactic activities [74]. Conversely,
cathepsin G also degrades CCL5, CCL3, CXCL12, and
CXCR4 to reduce PMN and monocyte chemotaxis
[75,76]. Cathepsin G is a potent platelet activator and
promotes intravascular thrombosis, thus contributing
to the formation of a thrombus clot [77].
Figure 3 Mechanisms of action of PMNs on post-MI LV
remodeling. Infiltrating PMNs release a wide range of cytokines and
chemokines, granule components, and reactive oxygen species,
which directly and indirectly regulate immune cell infiltration and
function to modulate remodeling response.
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Azurocidin, also known as cationic antimicrobial protein of
37 kDa (CAP37) or heparin-binding protein (HBP), is
stored in both azurophilic and secretory granules.
Azurocidin is released at both the very early phase and the
later phase of PMN recruitment to sites of inflammation
[78]. Azurocidin induces monocyte recruitment and en-
hances cytokine production in monocytes/macrophages,
signifying the ability of azurocidin to regulate monocytes/
macrophage infiltration and activation in the post-MI
setting [79-81]. The effect of azurocidin on leukocytes is
dependent on β2 integrins and the formyl peptide receptor.
Originally considered devoid of proteinase activity,
azurocidin can actually cleave insulin-like growth factor
binding protein-1, -2, and −4 in vitro [82]. The LTB4-
induced increase in vascular permeability is mediated by
azurocidin [83], suggesting that azurocidin may promote
leukocyte extravasation.
α-defensins
The α-defensins, also referred to as human neutrophil
peptides (HNPs), are small cationic antimicrobial peptides
mainly present in the azurophilic granules. The α-defensins
not only have antimicrobial function, but also possess
immunoregulatory properties mediated by direct inter-
action with innate immune cells [84]. HNP-1 and −2 are
potent chemoattractants for monocyte, naïve T cells, and
immature dendritic cells, but not for mature dendritic cells
or PMNs [85,86]. In addition, HNP-1 is able to activate
monocyte-derived dendritic cells and upregulate the
production of proinflammatory cytokines [87]. In view of
their immunoregulatory activities, future studies to explore
the functions of α-defensins in MI are warranted.
Lactoferrin
Lactoferrin is an iron-binding glycoprotein of the
transferrin family present in the specific granules. It
is also synthesized by epithelial cells [88]. In addition
to direct antimicrobial activity, lactoferrin inhibits the
upregulation of adhesion molecules, limits iron-mediated
damage to host tissue, suppresses proinflammatory cytokine
production, and limits PMN recruitment [89]. Post-MI,
lactoferrin may have protective effects by inhibiting
excessive inflammation and ROS production.
Cathelicidin
Cathelicidin, also known as cathelicidin-related antimicro-
bial peptide (CRAMP) in mouse and LL-37 or hCAP18 in
human, resides in specific granules. In addition to potent
microbicidal activity, LL-37 inhibits PMN apoptosis and
stimulates monocyte recruitment, angiogenesis, and tissue
regeneration [90]. LL37 elevates IL-1β-induced release of
cytokines (IL-6 and IL-10) and chemokines such as MCP-1,
MCP-3, and IL-8 in macrophages [91,92]. LL-37 deposits atsites of endothelial injury, facilitates re-endothelization, and
limits neointima formation after stent implantation by
enhancing early outgrowth cell recruitment and release of
growth factors [93]. Further, stents coated with LL-37 have
reduced re-stenosis, indicating that LL-37 may promote the
healing response [93]. Doring and colleagues show
that lack of CRAMP reduces atherosclerotic lesion
size by restraining monocyte recruitment and by
reducing the adhesion of classical monocytes and PMNs
in a formyl peptide receptor-dependent way [94]. In early
stages of atherosclerosis, CRAMP is specifically expressed
in PMNs, but not in monocytes or macrophages.
Therefore, cathelicidin may modulate LV remodeling
after MI by regulating leukocyte infiltration, apoptosis,
and angiogenesis.
MMP-25
MMP-25, also known as MT6-MMP or leukolysin, is
a membrane-type MMP. In PMNs, MMP-25 is
present in gelatinase granules and is also found in
nuclear/endoplasmic reticulum/Golgi fractions [95]. In
vitro studies show that MMP-25 cleaves CXCL5,
CCL15, and CCL23 to activate these chemokines, and
thus promotes the recruitment of PMNs and monocytes
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MMP-25 levels have not even been measured post-MI.
NETs
PMNs release granule antimicrobial proteins and nuclear
components (DNA, histones) into the extracellular environ-
ment that form NETs to trap invading pathogens. This
process is referred to as NETosis and is an alternative to
PMN apoptosis [97]. NETs degrade virulent factors and kill
microorganisms to prevent infection from spreading [98].
NETs also have detrimental influences on the host. NETs
activate the complement system, and the complement
component C1q can inhibit NETs degradation, thus
establishing a positive feedback loop to exacerbate disease
progression [99]. It has been shown that NETs facilitate
thrombosis in MI patients, probably by promoting fibrin
deposition and platelet aggregation [100]. The role of NETs
in the progression of MI-induced heart failure, however,
has not been investigated.
Conclusions
This review summarizes the roles of PMNs and
PMN-derived granule components in inflammation,
innate immunity, and MI. PMNs regulate the post-MI
wound healing response through several mechanisms
(Figure 3). PMNs are activated by cytokines and
chemokines, and activated PMNs in turn release cytokines
and chemokines to potentiate the inflammatory component
of wound healing [101]. PMN degranulation releases
an array of proteases that regulate LV remodeling by
modulating immune cell infiltration and function,
including ROS production. The PMN respiratory burst
generates ROS to directly modify biological molecules.
However, several aspects remain to be elucidated in order
to better understand PMN roles after MI.
First, PMN roles post-MI need to be better understood,
using systematic approaches that distinguish the negative
and positive roles. In order for therapeutic strategies to be
developed that promote healing while preventing adverse
remodeling, we need to better understand the complexity
of PMNs in mediating the early inflammatory response.
Second, there may be different activation phenotypes of
PMNs following MI [102-104]. A recent study by
Fridlender and colleagues suggests that tumor associated
PMNs can be polarized towards different phenotypes
[104]. Blocking TGF-β slows tumor growth by increasing
the influx of PMNs to produce higher levels of
proinflammatory cytokines, which are more cytotoxic
[104]. PMN depletion without TGF-β blockade, however,
also decreases tumor growth. TGF-β, therefore, promotes
a PMN pro-tumor phenotype, while blocking TGF-β
induces a PMN anti-tumor phenotype [104]. TGF-β
effects on tumors and the post-MI LV are likely opposite,
as TGF-β promotes post-MI infarct healing and blockingTGF-β increases MI-induced mortality and LV dilation
[105]. PMN phenotypes should be examined by isolating
PMNs from post-MI hearts at different time points and
measuring the expression of key effector molecules. Before
this can be accomplished, however, we need to determine
what markers can be used to differentiate phenotypes and
whether overall inflammatory status is sufficient.
Third, whether PMNs directly or indirectly regulate
macrophage polarization (M1 or M2 activation) or func-
tion is not currently well understood. This could be evalu-
ated by incubating resting macrophages with conditioned
media from activated PMNs and monitoring the macro-
phages for M1 and M2 markers [106]. It may be that
PMNs from different post-MI times promote differential
macrophage activation patterns.
Fourth, whether PMNs regulate cardiac fibroblast pheno-
type and post-MI scar formation is not known [107]. The
role of macrophages in activating fibroblasts has been stud-
ied, but whether PMNs exert similar or different activation
functions is unknown. This can be addressed by incubating
isolated cardiac fibroblasts with activated PMNs and meas-
uring fibroblast phenotype and secretion of extracellular
matrix [106].
In conclusion, understanding how PMNs regulate post-
MI LV remodeling may provide promising intervention
targets for MI patients. Understanding the detrimental
and beneficial roles will provide mechanistic insight into
how PMNs regulate inflammatory responses, both in the
MI setting and in other diseases that have inflammation as
a common response.
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